REG - ValiRx PLC - Director/PDMR Shareholding

ValiRxAnnouncement

07/07/2022 11:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220707:nRSG6907Ra&default-theme=true

RNS Number : 6907R  ValiRx PLC  07 July 2022

7 July 2022

 

ValiRx PLC ("ValiRx" or the "Company")

 

Directors' Dealing

 

ValiRX, a life science company focusing on early-stage cancer therapeutics and
women's health, announced 30 June 2022 that certain directors confirmed their
intention to participate in the Placing  that was announced on that date.

The table below sets out details of their participation in the Placing at a
price of 10 pence per share.

 Director          Ordinary Shares Purchased  Resultant Shareholding  % of Issued Share Capital
 Suzanne Dilly     100,000                    416,668                 0.46%
 Martin Lampshire  100,000                    144,000                 0.16%
 Kevin Cox         100,000                    372,333                 0.41%
 Gerry Desler      25,000                     128,668                 0.14%

 

*** ENDS ***

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company
take responsibility for this announcement.

For more information, please contact:

 

 ValiRx plc                                              Tel: +44 (0) 2476 796496

                                                         www.valirx.com (http://www.valirx.com)

 Dr Suzanne Dilly, CEO                                   Suzanne.Dilly@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)        Tel: +44 (0) 20 7213 088

 Liam Murray/Jo Turner/Ludovico Lazzaretti

 Cenkos Securities Limited (Joint Broker)                Tel: +44 (0) 20 7397 8900

 Russell Kerr/Michael Johnson (Sales)

 Callum Davidson/Giles Balleny (Corporate Finance)
 Turner Pope Investments (TPI) Limited  (Joint Broker)   Tel: +44 (0) 20 3657 0050

 James Pope / Andy Thacker

 

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's
health to improve patient lives. We provide the scientific, financial and
commercial framework towards enabling rapid translation of innovative science
into clinical development.

With our extensive and proven experience in research and drug development, we
select and incubate promising novel drug candidates and guide them through an
optimised process of development, from pre-clinical studies to clinic and
investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial
domains, with the aim of achieving a more streamlined, less costly, drug
development process.  We work closely with our selected collaborators and
leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation. https://www.valirx.com/ (https://www.valirx.com/)

The Company listed on the AIM Market of the London Stock Exchange in October
2006 and trades under the ticker symbol: VAL.

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         a) Suzanne Dilly
                                                                  b) Martin Lampshire
                                                                  c) Kevin Cox
                                                                  d) Gerry Desler

 
 2   Reason for notification
 a.  Position/Status                                              a) Director

                                                                  b) Director

                                                                  c) Director

                                                                  d) Director
 b.  Initial notification/                                        Initial notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         ValiRx PLC
 b.  LEI                                                          213800VQKB9SJCQDET40

 
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary Shares

Identification Code

                                                                   ISIN: GB00BLH13C52
 b.  Nature of the transaction                                    Purchase of shares as part of the Placing
 c.  Price(s) and volume(s)
                                                                              Price(s)    Volume(s)
     a) 10p                                                                                           a) 100,000
     b) 10p                                                                                           b) 100,000
     c) 10p                                                                                           c) 100,000
     d) 10p                                                                                           d)  25,000

 
 

 d.  Aggregated information

     - Aggregated Volume                                          N/A

     - Price
 e.  Date of the transaction                                      a) 07/07/2022
                                                                  b) 07/07/2022
                                                                  c) 07/07/2022
                                                                  d) 07/07/2022

 
 f.  Place of the transaction                                     London, UK

 

2

Reason for notification

a.

Position/Status

a) Director

b) Director

c) Director

d) Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a.

Name

ValiRx PLC

b.

LEI

   213800VQKB9SJCQDET40

 

4

Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary Shares

 

 ISIN: GB00BLH13C52

b.

Nature of the transaction

Purchase of shares as part of the Placing

c.

Price(s) and volume(s)

Price(s)

Volume(s)

 a) 10p
 b) 10p
 c) 10p
 d) 10p

 

 a) 100,000
 b) 100,000
 c) 100,000
 d)  25,000

 

d.

Aggregated information

- Aggregated Volume

- Price

 

N/A

 

e.

Date of the transaction

 a) 07/07/2022
 b) 07/07/2022
 c) 07/07/2022
 d) 07/07/2022

 

f.

Place of the transaction

London, UK

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBGGDRUGGDGDR